Rapid Efficacy of riSankizumab in pretibial psoriasis invOLVEment: RESOLVE.

Q2 Pharmacology, Toxicology and Pharmaceutics

Drugs in Context Pub Date : 2024-09-05 eCollection Date: 2024-01-01 DOI:10.7573/dic.2024-6-3

Nicoletta Bernardini, Nevena Skroza, Laura Atzori, Cristina Mugheddu, Matteo Megna, Sara Cacciapuoti, Michela Ortoncelli, Maria A Montesu, Antonio Carpentieri, Martino Carriero, Maria G Atzori, Gianmario Addis, Riccardo Balestri, Giulia Rech, Pierluigi Bruni, Manuela Papini, Concetta Potenza

{"title":"Rapid Efficacy of riSankizumab in pretibial psoriasis invOLVEment: RESOLVE.","authors":"Nicoletta Bernardini, Nevena Skroza, Laura Atzori, Cristina Mugheddu, Matteo Megna, Sara Cacciapuoti, Michela Ortoncelli, Maria A Montesu, Antonio Carpentieri, Martino Carriero, Maria G Atzori, Gianmario Addis, Riccardo Balestri, Giulia Rech, Pierluigi Bruni, Manuela Papini, Concetta Potenza","doi":"10.7573/dic.2024-6-3","DOIUrl":null,"url":null,"abstract":"Background: Despite extraordinary improvements in the management of psoriasis in recent times, some areas of the body, such as the pretibial area, still show an unsatisfactory response and a more significant impact on patient quality of life. This multicentre study focuses on psoriasis affecting sensitive areas (particularly the pretibial area), its impact on quality of life and the therapeutic response to risankizumab.Methods: This multicentre prospective observational study recruited patients with moderate-to-severe psoriasis with pretibial area involvement. All patients underwent treatment with risankizumab (150 mg every 3 weeks), and efficacy was assessed after 24 weeks.Results: The study included 128 patients with a mean age of 51 years, suffering from moderate-to-severe psoriasis with involvement of the pretibial area with median total Psoriasis Area Severity Index score of 17.05 and Dermatology Life Quality Index of 16.27. The group was further divided into two sub-groups: the 'mother patch' group, in whom the very first psoriatic plaque appeared in the pretibial region (45 patients), and the 'non-mother patch' group, in whom the psoriatic lesion in the pretibial region was present but not as the first manifestation (83 patients). In order to better assess the involvement of psoriasis in the pretibial area, the pretibial plaque lesion severity index was also calculated at baseline in all patients: extent 2.75, erythema 2.64, infiltration 2.45 and desquamation 2.38. All participants in this study showed a good therapeutic response, with a reduction in all scores.Conclusions: The pretibial area is becoming an object of therapeutic interest due to some resistance to clearance and the consequent impairment of patient quality of life. This study showed that risankizumab can give favourable therapeutic results not only in patients with moderate-to-severe psoriasis with involvement of the difficult-to-treat areas but particularly in patients with recalcitrant plaques in the pretibial area.","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"13 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11389876/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs in Context","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7573/dic.2024-6-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Despite extraordinary improvements in the management of psoriasis in recent times, some areas of the body, such as the pretibial area, still show an unsatisfactory response and a more significant impact on patient quality of life. This multicentre study focuses on psoriasis affecting sensitive areas (particularly the pretibial area), its impact on quality of life and the therapeutic response to risankizumab.

Methods: This multicentre prospective observational study recruited patients with moderate-to-severe psoriasis with pretibial area involvement. All patients underwent treatment with risankizumab (150 mg every 3 weeks), and efficacy was assessed after 24 weeks.

Results: The study included 128 patients with a mean age of 51 years, suffering from moderate-to-severe psoriasis with involvement of the pretibial area with median total Psoriasis Area Severity Index score of 17.05 and Dermatology Life Quality Index of 16.27. The group was further divided into two sub-groups: the 'mother patch' group, in whom the very first psoriatic plaque appeared in the pretibial region (45 patients), and the 'non-mother patch' group, in whom the psoriatic lesion in the pretibial region was present but not as the first manifestation (83 patients). In order to better assess the involvement of psoriasis in the pretibial area, the pretibial plaque lesion severity index was also calculated at baseline in all patients: extent 2.75, erythema 2.64, infiltration 2.45 and desquamation 2.38. All participants in this study showed a good therapeutic response, with a reduction in all scores.

Conclusions: The pretibial area is becoming an object of therapeutic interest due to some resistance to clearance and the consequent impairment of patient quality of life. This study showed that risankizumab can give favourable therapeutic results not only in patients with moderate-to-severe psoriasis with involvement of the difficult-to-treat areas but particularly in patients with recalcitrant plaques in the pretibial area.

查看原文本刊更多论文

riSankizumab 对胫前银屑病的快速疗效：RESOLVE.

背景：尽管近来银屑病的治疗有了显著改善，但身体的某些部位，如胫骨前区域，仍显示出不尽人意的反应，并对患者的生活质量造成较大影响。这项多中心研究的重点是影响敏感区域（尤其是胫前区域）的银屑病、其对生活质量的影响以及利桑珠单抗的治疗反应：这项多中心前瞻性观察研究招募了胫前区域受累的中重度银屑病患者。所有患者均接受利坦珠单抗治疗（每3周150毫克），24周后评估疗效：研究共纳入128名患者，平均年龄51岁，患有中度至重度银屑病，胫前部位受累，银屑病面积严重程度指数中位数为17.05，皮肤科生活质量指数为16.27。该组又分为两个亚组："母斑 "组和 "非母斑 "组。前者的银屑病斑块最早出现在胫前区域（45 名患者），后者的银屑病皮损出现在胫前区域，但不是首发症状（83 名患者）。为了更好地评估胫前银屑病的累及情况，我们还计算了所有患者胫前斑块的基线皮损严重程度指数：范围 2.75，红斑 2.64，浸润 2.45，脱屑 2.38。这项研究的所有参与者都表现出了良好的治疗反应，所有评分都有所下降：结论：胫骨前区域由于对清除有一定的抵抗力，因此正在成为治疗关注的对象，并因此损害了患者的生活质量。这项研究表明，利桑珠单抗不仅能对累及难治区域的中重度银屑病患者产生良好的治疗效果，而且对胫骨前区域顽固斑块患者的治疗效果尤为显著。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drugs in Context Medicine-Medicine (all)

CiteScore

5.90

自引率

0.00%

发文量

审稿时长

9 weeks

期刊介绍： Covers all phases of original research: laboratory, animal and human/clinical studies, health economics and outcomes research, and postmarketing studies. Original research that shows positive or negative results are welcomed. Invited review articles may cover single-drug reviews, drug class reviews, latest advances in drug therapy, therapeutic-area reviews, place-in-therapy reviews, new pathways and classes of drugs. In addition, systematic reviews and meta-analyses are welcomed and may be published as original research if performed per accepted guidelines. Editorials of key topics and issues in drugs and therapeutics are welcomed. The Editor-in-Chief will also consider manuscripts of interest in areas such as technologies that support diagnosis, assessment and treatment. EQUATOR Network reporting guidelines should be followed for each article type. GPP3 Guidelines should be followed for any industry-sponsored manuscripts. Other Editorial sections may include Editorial, Case Report, Conference Report, Letter-to-the-Editor, Educational Section.